MedTrace Logo

Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors

NCT06258330 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-01-28

No results posted yet for this study

Summary

This is a phase 1, first-in-human study to assess the safety and tolerability of AM003 in patients with locally advanced and metastatic solid tumors

Conditions

Interventions

DRUG

AM003

Bispecific Personalized Aptamer for intratumoral administration

Sponsors & Collaborators

  • Aummune Ltd.

    lead INDUSTRY

Principal Investigators

  • Irit Carmi Levy, PhD · GM and Chief Scientific Officer Aummune

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-22
Primary Completion
2024-07-07
Completion
2024-10-01

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06258330 on ClinicalTrials.gov